Drug Type Small molecule drug |
Synonyms (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol, 2-Chloro-2'-deoxy-beta-adenosine, 2-Chloro-2'-deoxyadenosine + [24] |
Target |
Mechanism RNR inhibitors(Ribonucleotide reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (26 Feb 1993), |
RegulationOrphan Drug (US), Orphan Drug (EU), Orphan Drug (JP) |
Molecular FormulaC10H12ClN5O3 |
InChIKeyPTOAARAWEBMLNO-KVQBGUIXSA-N |
CAS Registry4291-63-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01370 | Cladribine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | US | 29 Mar 2019 | |
Multiple sclerosis relapse | EU | 22 Aug 2017 | |
Multiple sclerosis relapse | IS | 22 Aug 2017 | |
Multiple sclerosis relapse | LI | 22 Aug 2017 | |
Multiple sclerosis relapse | NO | 22 Aug 2017 | |
Anemia | CN | 15 Nov 2005 | |
Neutropenia | CN | 15 Nov 2005 | |
Thrombocytopenia | CN | 15 Nov 2005 | |
Mantle-Cell Lymphoma | JP | 16 Dec 2002 | |
Non-Hodgkin Lymphoma | JP | 16 Dec 2002 | |
Hairy Cell Leukemia | US | 26 Feb 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myasthenia Gravis | Phase 3 | US | 17 Jun 2024 | |
Myasthenia Gravis | Phase 3 | DE | 17 Jun 2024 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | - | 01 Apr 2005 | |
Acute Myeloid Leukemia | Phase 2 | US | 01 Dec 2024 | |
Neuromyelitis Optica | Preclinical | CH | Chord Therapeutics SAStartup | 01 Jun 2020 |
Phase 4 | 280 | cbsqtzfyks(qcaydewkhl) = zvumtjnbay bezolylrko (mcdclnooxe, xwylqyaxif - rxdsrlaaae) View more | - | 28 May 2024 | |||
Not Applicable | - | - | lkecfugmzq(tnitaiqvpx) = TRM, nausea and acute GvHD frequency was lower with cladribine (p=0.35, p=0.001 and p=0.02, respectively). Typhilitis and perianal infections were more common with cladribine (p=0.07 and p=0.04, respectively) uaeljojvtq (kxfrgxmzit ) | - | 24 May 2024 | ||
Not Applicable | Hairy Cell Leukemia BRAF V600E mutation | 7 | rfjrgqhvoq(kahitospir) = Complete remission was obtained in all pts avnklzwzaa (ompxberixx ) View more | Positive | 14 May 2024 | ||
Not Applicable | - | nzzuhjafsj(ztleabnpwn) = 8% ocqhrxkftp (fqbltimwie ) View more | - | 14 May 2024 | |||
NCT01439750 (AACR2024) Manual | Phase 1 | 13 | gqjnhnxmtb(nqsdprbsgz) = No subject experienced dose limited toxicity (DLT) at either level 1 or 2, one possible DLT (infectious colitis) was observed on a subject during 2nd cycle at level 3. Then no additional DLTs were seen in 3 subjects added to level 3 sgqdeojmhf (hamsqvsejt ) View more | Positive | 05 Apr 2024 | ||
Not Applicable | - | miysnuqces(qgvnhehoxb) = self-reported adherence rates to the full first year treatment course was high at ≥97.3% for patients with prior oral DMT and 100% for patients with prior infusion DMT, including ocrelizumab ftvgrnaflk (ewvxrhnwce ) View more | - | 01 Mar 2024 | |||
Not Applicable | 4 | rxefgvdjmc(tbkysyfxwq) = wbvqzfqlsn esgzlqzrtr (cyxchforve ) | Positive | 01 Mar 2024 | |||
rxefgvdjmc(tbkysyfxwq) = btkgatvdwm esgzlqzrtr (cyxchforve ) | |||||||
Not Applicable | 164 | zpwninbbpo(qxnsqdeuco) = amfntdqnha ecswfncjkk (vmzixcrxdo ) | Positive | 01 Mar 2024 | |||
zpwninbbpo(qxnsqdeuco) = cpffnahyto ecswfncjkk (vmzixcrxdo ) | |||||||
Not Applicable | 847 | acynfwleuw(oeykspkxhf) = qihiqbaref jwallcpjvn (slkyhczizf ) View more | Positive | 01 Mar 2024 | |||
acynfwleuw(oeykspkxhf) = rkxxknyzda jwallcpjvn (slkyhczizf ) | |||||||
Not Applicable | S1P (Sphingosine-1-phosphate) receptor modulators | 111 | Cladribine tablets (CladT) | xjhtvvvhzt(dehlwhlwdc) = seqndfnjyz ujelikfgew (tcsctxnzdz ) View more | Positive | 01 Mar 2024 | |
Sphingosine-1-phosphate (S1P) receptor modulators | xjhtvvvhzt(dehlwhlwdc) = fjynnvpeut ujelikfgew (tcsctxnzdz ) |